<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Omada Health — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>

<header class="site-header">
  <h1>Prospect Detail</h1>
</header>

<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>

  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>35. Omada Health</h1>
    <p class="meta">Virtual Chronic Care Platform</p>
  </div>

  <div class="section">
    <h3>1. Startup Name</h3>
    <p><strong>Omada Health</strong></p>
  </div>

  <div class="section">
    <h3>2. Founder Contact</h3>
    <p><strong>Sean Duffy, MD MBA</strong> — Co-Founder & CEO</p>
    <p>Harvard Medical School MD, Harvard Business School MBA</p>
  </div>

  <div class="section">
    <h3>3. Product Overview</h3>
    <p>Omada Health is a virtual-first chronic care management platform addressing diabetes, hypertension, prediabetes, weight management, and musculoskeletal conditions. Care teams implement clinically-validated behavior change protocols, combining digital tools, coaching, and connected devices to improve outcomes at scale.</p>
  </div>

  <div class="section">
    <h3>4. Funding Stage</h3>
    <p><strong>Late Stage</strong> — Raised over $500M total from top-tier investors including General Catalyst, Andreessen Horowitz, and Cigna Ventures. Valued at approximately $1B+.</p>
  </div>

  <div class="section">
    <h3>5. How I Found the Company</h3>
    <p>Discovered as a prominent Harvard HMS/HBS alumni success story in digital health, frequently cited in Rock Health reports and healthcare venture discussions.</p>
  </div>

  <div class="strengths-weaknesses">
    <div class="section">
      <h3>Strengths</h3>
      <ul>
        <li><strong>Clinical evidence:</strong> Multiple peer-reviewed studies demonstrating outcomes, including CDC-recognized Diabetes Prevention Program.</li>
        <li><strong>Scale and enterprise relationships:</strong> Works with major employers and health plans covering millions of lives.</li>
      </ul>
    </div>
    <div class="section">
      <h3>Weaknesses</h3>
      <ul>
        <li><strong>Late-stage valuation:</strong> May be less attractive for early-stage investment thesis given existing scale.</li>
        <li><strong>Competitive pressure:</strong> Livongo (now Teladoc), Virta Health, and others compete aggressively in chronic care space.</li>
      </ul>
    </div>
  </div>

  <div class="section">
    <h3>7. Five Questions for the Team</h3>
    <ol class="questions-list">
      <li>What is your current member enrollment and annual retention rate?</li>
      <li>How do you differentiate from Livongo/Teladoc's integrated chronic care offerings?</li>
      <li>What is your path to profitability and current burn rate?</li>
      <li>How are you expanding into new condition categories beyond diabetes?</li>
      <li>What are your IPO or exit timeline considerations?</li>
    </ol>
  </div>

  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>

</body>
</html>
